Cryo-Cell International (NYSEAMERICAN:CCEL) Shares Cross Below Two Hundred Day Moving Average – Here’s What Happened

Cryo-Cell International Inc. (NYSEAMERICAN:CCEL)’s stock price crossed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $4.36 and traded as low as $3.41. Cryo-Cell International shares last traded at $3.44, with a volume of 5,874 shares traded.

Analyst Ratings Changes

Separately, Maxim Group cut Cryo-Cell International from a “buy” rating to a “hold” rating in a research report on Monday, October 20th. One investment analyst has rated the stock with a Hold rating, Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $8.50.

Cryo-Cell International Trading Up 0.9%

The company has a market capitalization of $27.73 million, a P/E ratio of -49.14 and a beta of 0.57. The company’s fifty day moving average is $3.80 and its 200 day moving average is $4.36.

Cryo-Cell International (NYSEAMERICAN:CCEL) last posted its earnings results on Wednesday, October 15th. The company reported $0.09 earnings per share (EPS) for the quarter. The company had revenue of $7.83 million for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Cryo-Cell International stock. Susquehanna International Group LLP purchased a new stake in shares of Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 11,062 shares of the company’s stock, valued at approximately $51,000. Susquehanna International Group LLP owned 0.14% of Cryo-Cell International as of its most recent SEC filing. 10.44% of the stock is owned by institutional investors and hedge funds.

Cryo-Cell International Company Profile

Cryo-Cell International, Inc is a pioneering provider of umbilical cord blood and tissue preservation services. Headquartered in Oldsmar, Florida, the company was founded in 1989 as the first private cord blood bank in the United States. Cryo-Cell operates FDA-registered and AABB-accredited laboratory facilities, maintaining stringent quality control measures and cryogenic storage systems to safeguard stem cell viability over long-term storage periods.

The company’s primary business activity centers on the collection, processing and secure storage of newborn stem cell sources harvested at birth.